BioMS clinical proteomics

The entire approach how we diagnose and make treatment decisions is undergoing a paradigm shift in form of precision medicine, where targeted drugs are tailored for an individual patient based on extensive and informative biomarker data. To make precision medicine reality, vast research efforts has been initiated in Sweden and worldwide.

Precision medicine field is in part technology driven and internationally, the field is rapidly moving toward including proteome analysis to represent the molecular phenotype.

The adoption of proteome analysis is catalyzed by revolutionary developments in the proteomics field by a new MS approach, so-called data-independent acquisition MS (DIA-MS) and related targeted multiplex MS-analysis PRM, coupled with developments in high throughput chromatography and automation in sample preparation.

These developments have solved problems with generation of robust high-content data in large clinical cohorts.

To leverage Swedish investments in clinical research and genome medicine, a previous platform investment in the already established BioMS environment will allow rapid service built up in clinical proteomics, to provide unique service capabilities for Swedish researchers.

The BioMS nodes have considerable expertise and have previously performed internationally competitive studies in the clinical proteomics field.

Here, we apply for mirrored robotics for sample-prep automation and DIA-MS instruments cross 3 nodes to allow harmonized clinical proteomics development cross country and support for multi-site clinical trials.

With this instrument support delineated here, BioMS can be the first national infrastructure in the world that provides prospective clinical proteomics research support.

This will catalyze biomedical research field in Sweden and add proteome layer in multi-omics studies and connected cutting edge MS-technologies to prospective clinical trials.